公开(公告)号：US20240360082A1

公开(公告)日：2024-10-31

申请号：US18291083

申请日：2022-07-22

Applicant: NOVARTIS AG

Inventor： Graham Charles BLOOMFIELD ,  Matthew James HESSE ,  Richard Yichong HUANG ,  Michael Robert MASER ,  James Clifford SUTTON ,  Benjamin Robert TAFT ,  David Charles TULLY

IPC: C07D213/82 ,  A61K31/4418 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/498 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/553 ,  C07D401/10 ,  C07D401/12 ,  C07D405/10 ,  C07D405/14 ,  C07D409/12 ,  C07D413/10 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D491/052 ,  C07D493/08 ,  C07D493/10 ,  C07D498/04 ,  C07D498/08 ,  C07D498/10

CPC classification number: C07D213/82 ,  A61K31/4418 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/498 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/553 ,  C07D401/10 ,  C07D401/12 ,  C07D405/10 ,  C07D405/14 ,  C07D409/12 ,  C07D413/10 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D491/052 ,  C07D493/08 ,  C07D493/10 ,  C07D498/04 ,  C07D498/08 ,  C07D498/10

Abstract: The disclosure provides compounds of Formula (I): (I) as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.

公开(公告)号：US20240336574A1

公开(公告)日：2024-10-10

申请号：US18280891

申请日：2022-03-10

Applicant: LATIGO BIOTHERAPEUTICS, INC. ,  LIEBER INSTITUTE, INC.

Inventor： Robert M. Jones ,  Ashok Bajji ,  Nathaniel Julius Thomas Monck ,  Suzanne J. O'Connor ,  William H. Gardiner ,  Robert James Townsend ,  Andreina Pacheco Pita ,  Michael Brunavs ,  Abdul Kadar Shaikh ,  Jonathan Paul Shine ,  Ian James Wigginton ,  Jonathan Philip Richards ,  Marco Michele Mastandrea ,  Adam James Davenport ,  Bryan Moyer ,  Michael Poslusney ,  James Barrow ,  Richard Edmund Rathmell

IPC: C07D237/24 ,  A61K31/455 ,  A61K31/4725 ,  A61K31/50 ,  A61K31/501 ,  A61K31/502 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  C07D213/82 ,  C07D237/26 ,  C07D239/26 ,  C07D241/24 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/04 ,  C07D405/12 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12 ,  C07D471/04

CPC classification number: C07D237/24 ,  A61K31/455 ,  A61K31/4725 ,  A61K31/50 ,  A61K31/501 ,  A61K31/502 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  C07D213/82 ,  C07D237/26 ,  C07D239/26 ,  C07D241/24 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/04 ,  C07D405/12 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12 ,  C07D471/04

Abstract: The invention provides methyl-substituted pyridine and pyridazine compounds, derivatives thereof, and methods of their use. The compounds are useful as pharmacological agents to treat a variety of conditions, including various pain states, itch, and cough.

公开(公告)号：US20240327381A1

公开(公告)日：2024-10-03

申请号：US18435117

申请日：2024-02-07

Applicant: Celgene Corporation ,  Bristol-Myers Squibb Company

Inventor： Laura Akullian D'Agostino ,  Godwin Kumi ,  Haibo Liu

IPC: C07D401/14 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/498 ,  C07D401/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D451/00 ,  C07D471/04

CPC classification number: C07D401/14 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/498 ,  C07D401/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D451/00 ,  C07D471/04

Abstract: Provided herein are compounds and compositions thereof for degrading an engineered polypeptide in a cell. In some embodiments, the compounds and compositions are provided for treatment of cancer.

公开(公告)号：US20240315971A1

公开(公告)日：2024-09-26

申请号：US18592719

申请日：2024-03-01

Applicant: Lotus BioPharma Inc.

Inventor： Chao Li ,  Nancy L. Li ,  Kingteh Lin

IPC: A61K9/16 ,  A61K31/137 ,  A61K31/18 ,  A61K31/216 ,  A61K31/4025 ,  A61K31/426 ,  A61K31/4725

CPC classification number: A61K9/1647 ,  A61K9/1694 ,  A61K31/137 ,  A61K31/18 ,  A61K31/216 ,  A61K31/4025 ,  A61K31/426 ,  A61K31/4725

Abstract: This disclosure provides injectable microsphere formulations capable of controlled long-term sustained release. The disclosed microsphere formulations demonstrate a zero-order release of active agents over a predetermined period of time. Also disclosed are methods of preparing the microsphere formulations and methods of use thereof. The disclosed methods can be readily scaled up while maintaining a high drug encapsulation efficiency.

公开(公告)号：US20240294524A1

公开(公告)日：2024-09-05

申请号：US18632638

申请日：2024-04-11

Applicant: Viracta Therapeutics, Inc. ,  Millennium Pharmaceuticals, Inc.

Inventor： Joseph ARNDT ,  Timothy CHAN ,  Kevin GUCKIAN ,  Gnanasambandam KUMARAVEL ,  Wen-Cherng LEE ,  Edward Yin-Shiang LIN ,  Daniel SCOTT ,  Lihong SUN ,  Jermaine THOMAS ,  Kurt VAN VLOTEN ,  Deping WANG ,  Lei ZHANG ,  Daniel ERLANSON

IPC: C07D471/04 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/452 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/517 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/5383 ,  C07D213/82 ,  C07D213/85 ,  C07D241/26 ,  C07D241/28 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D417/14 ,  C07D473/34 ,  C07D487/04 ,  C07D491/052 ,  C07D498/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/452 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/517 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/5383 ,  C07D213/82 ,  C07D213/85 ,  C07D241/26 ,  C07D241/28 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D417/14 ,  C07D473/34 ,  C07D487/04 ,  C07D491/052 ,  C07D498/04 ,  C07D519/00

Abstract: The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.

公开(公告)号：US20240293391A1

公开(公告)日：2024-09-05

申请号：US18567504

申请日：2022-06-24

Applicant: Katholieke Universiteit Leuven

Inventor： Wim DEHAEN ,  Steven DE JONGHE ,  Dominique SCHOLS ,  Tom VAN LOY

IPC: A61K31/4725 ,  A61K31/47 ,  A61K31/4709 ,  A61P31/18 ,  C07D215/06 ,  C07D401/12

CPC classification number: A61K31/4725 ,  A61K31/47 ,  A61K31/4709 ,  A61P31/18 ,  C07D215/06 ,  C07D401/12

Abstract: The invention relates to isoquinoline and pyridine based CXCR4 antagonists and their use in the treatment and prevention of viral infections such as HIV.

公开(公告)号：US20240285611A1

公开(公告)日：2024-08-29

申请号：US18450394

申请日：2023-08-15

Applicant: ABBVIE INC.

Inventor： Le WANG ,  George DOHERTY ,  Xilu WANG ,  Zhi-Fu TAO ,  Milan BRUNCKO ,  Aaron R. KUNZER ,  Michael D. WENDT ,  Xiaohong SONG ,  Robin FREY ,  Todd M. HANSEN ,  Gerard M. SULLIVAN ,  Andrew JUDD ,  Andrew SOUERS

IPC: A61K31/4725 ,  A61K31/4985 ,  A61K31/5025 ,  A61K31/5377 ,  A61K31/541 ,  C07D401/04 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D493/08 ,  C07D513/04

CPC classification number: A61K31/4725 ,  A61K31/4985 ,  A61K31/5025 ,  A61K31/5377 ,  A61K31/541 ,  C07D401/04 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D493/08 ,  C07D513/04

Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.

公开(公告)号：US20240279202A1

公开(公告)日：2024-08-22

申请号：US18289513

申请日：2022-05-03

Applicant: NURIX THERAPEUTICS, INC.

Inventor： Joel MCINTOSH ,  Daisuke KATO ,  Jeffrey MIHALIC ,  Ge PENG

IPC: C07D401/14 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/513 ,  C07D471/10

CPC classification number: C07D401/14 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/513 ,  C07D471/10

Abstract: Provided herein are compounds for inhibiting and/or degrading IL-2 inducible T-cell kinase (ITK), compositions comprising the compounds, methods of making the same, and methods of their use for treating diseases or disorders including cancer, inflammatory, and autoimmune diseases.

公开(公告)号：US20240277698A1

公开(公告)日：2024-08-22

申请号：US18569853

申请日：2022-06-24

Applicant: CINCOR PHARMA, INC.

Inventor： Mary BOND ,  Brian MURPHY ,  Catherine PEARCE

IPC: A61K31/4725 ,  A61P9/12

CPC classification number: A61K31/4725 ,  A61P9/12

Abstract: The disclosure provides methods of inhibiting human aldosterone synthase, treating hypertension, or treating primary aldosteronism in a subject in need thereof, comprising administering an effective amount of (R)-Compound 1 to the subject, wherein (R)-Compound 1 is: Formula (I).

公开(公告)号：US12065416B2

公开(公告)日：2024-08-20

申请号：US18158046

申请日：2023-01-23

Applicant: IMMUNESENSOR THERAPEUTICS, INC. ,  THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Boyu Zhong ,  Lijun Sun ,  Heping Shi ,  Jing Li ,  Chuo Chen ,  Zhijian Chen

IPC: C07D277/34 ,  A61K31/381 ,  A61K31/426 ,  A61K31/427 ,  A61K31/429 ,  A61K31/433 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/506 ,  A61K31/519 ,  A61K39/39 ,  A61K45/06 ,  C07D277/36 ,  C07D277/40 ,  C07D403/06 ,  C07D417/04 ,  C07D417/06 ,  C07D417/10 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D495/04 ,  C07D513/04

CPC classification number: C07D277/34 ,  A61K31/381 ,  A61K31/426 ,  A61K31/427 ,  A61K31/429 ,  A61K31/433 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/506 ,  A61K31/519 ,  A61K39/39 ,  A61K45/06 ,  C07D277/36 ,  C07D277/40 ,  C07D403/06 ,  C07D417/04 ,  C07D417/06 ,  C07D417/10 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D495/04 ,  C07D513/04 ,  A61K31/4439 ,  A61K2300/00 ,  A61K31/4709 ,  A61K2300/00 ,  A61K31/426 ,  A61K2300/00 ,  A61K31/4365 ,  A61K2300/00 ,  A61K31/429 ,  A61K2300/00 ,  A61K31/519 ,  A61K2300/00 ,  A61K31/381 ,  A61K2300/00 ,  A61K31/427 ,  A61K2300/00 ,  A61K31/433 ,  A61K2300/00 ,  A61K31/437 ,  A61K2300/00 ,  A61K31/506 ,  A61K2300/00

Abstract: Disclosed are novel compounds of Formula I that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.